Shionogi confirms efficacy of oral COVID drug for omicron subvariant

Japanese pharmaceutical agency Shionogi & Co. mentioned Wednesday its oral COVID-19 drug at present beneath improvement has been confirmed in preclinical testing to be efficient in opposition to the omicron subvariant BA.2.75, which has been detected in Japan.

The announcement got here after a well being ministry panel in July postponed the granting of emergency approval for the drug. Discussions are slated to renew after the outcomes of the ultimate stage of scientific trials at present underway.

Leave a Reply

Your email address will not be published.